Wavelength-Pharmaceuticals-Insert
X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: F. Hoffmann-La Roche

            Deal Size: $1,040.0 million Upfront Cash: $40.0 million

            Deal Type: Collaboration July 21, 2020

            Details:

            Under the terms of the agreement, Jnana will partner with Roche on discovery and preclinical development for a broad set of targets across immunology and neuroscience, which Roche will further develop and commercialize exclusively.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): NK cell Engager Therapies

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Bristol-Myers Squibb

            Deal Size: Undisclosed Upfront Cash: $55.0 million

            Deal Type: Licensing Agreement July 06, 2020

            Details:

            Under the agreement, Dragonfly will grant Bristol Myers Squibb the option to license exclusive worldwide intellectual property rights to multiple candidates developed using Dragonfly's proprietary platform for multiple new targets.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tecovirimat

            Therapeutic Area: Immunology Product Name: Tpoxx

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: BARDA

            Deal Size: $414.0 million Upfront Cash: Undisclosed

            Deal Type: Agreement June 25, 2020

            Details:

            SIGA Technologies, Inc. (SIGA) (NASDAQ: SIGA), a commercial-stage pharmaceutical company focused on the health security market, today announced the deliveries of oral TPOXX® (tecovirimat) to the U.S. Department of Health and Human Services (HHS).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Tecovirimat

            Therapeutic Area: Immunology Product Name: Tpoxx

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: JPEO-CBRND

            Deal Size: $23.0 million Upfront Cash: Undisclosed

            Deal Type: Funding June 15, 2020

            Details:

            Funding will support work necessary to gain a potential label expansion from the U.S. FDA for TPOXX® (tecovirimat) for Post-Exposure Prophylaxis (PEP) in addition to the current approved labeling for the treatment of smallpox.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Small molecule

            Partner/Sponsor/Collaborator: S.R. One

            Deal Size: $65.0 million Upfront Cash: Undisclosed

            Deal Type: Series B Financing May 21, 2020

            Details:

            The Series B financing will support the advancement of HotSpot’s lead programs to the clinic, including protein kinase C (PKC-theta) antagonists for Th2 and T-reg driven autoimmune disease and S6 kinase (S6K) antagonists for rare metabolic disease.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Synthetic AAV capsids Proteins

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable May 12, 2020

            Details:

            The presentation will highlight results from Dyno's study on Artificial intelligence powered design of synthetic AAV capsids without pre-existing immunity for the universal treatment of all patients.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Versant Ventures

            Deal Size: $60.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing May 06, 2020

            Details:

            Proceeds will be used to advance three pipeline programs and to expand the company’s structural immunology platform to pursue previously intractable drug targets.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Undisclosed

            Therapeutic Area: Immunology Product Name: Undisclosed

            Highest Development Status: Discovery Product Type: Undisclosed

            Partner/Sponsor/Collaborator: RA Capital Management

            Deal Size: $50.0 million Upfront Cash: Undisclosed

            Deal Type: Series A Financing January 27, 2020

            Details:

            The funding will support company's lead therapeutic approach that inhibits Gasdermin D, which has been recently discovered as a key target at the core of multiple inflammatory cell death pathways.